Abstract: The present application relates to the field of pharmaceutical preparations and relates to [1,2,4]triazolo [1,5-a]pyridine compounds and their isomers or pharmaceutically acceptable salts or their crystal forms, as well as local topical preparations and their applications in skin diseases. Specifically, it relates to a local topical formulations of compound (S)—N-(5-(2-(2,2-difluorocyclopropanecarbonyl)-2-nitrospiro[3.5]non-7-yl)-[1,2,4-triazole[1,5-a]pyridine-2-yl) cyclopropaneformamide and its isomers or pharmaceutically acceptable salts or crystal forms, and their applications in skin diseases. The preferred skin diseases include psoriasis, atopic dermatitis, vitiligo, lupus erythematosus, alopecia areata, eczema, contact dermatitis, urticaria, pompholyxs, dermatomyositis, scleroderma, acne, and seborrheic dermatitis.

Abstract: An oral preparation, specifically including a JAK inhibitor and pharmaceutical excipients is provided, wherein the JAK inhibitor includes a compound of formula (I), an isomer thereof, pharmaceutically acceptable salts thereof, or their crystal form. The oral preparation of the present application has the characteristic of rapid dissolution. The oral preparation process of the present application is simple and suitable for large-scale industrial production.

Abstract: Disclosed is the use of a JAK inhibitor [1,2,4]-triazolo-[1,5-a]0pyridine compound in the preparation of drugs for treating autoimmune, inflammatory or allergic diseases, or diseases such as transplant rejection. The JAK inhibitor [1,2,4]-triazolo-[1,5-a]-pyridine compound comprises a compound as shown in formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof. The JAK inhibitor has a good efficacy in animal model tests of diseases such as autoimmune, inflammatory or allergic diseases.